ReviewInternational journal of hepatology2021
Emerging Roles of Impaired Autophagy in Fatty Liver Disease and Hepatocellular Carcinoma.
Review in International journal of hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05733897 (Using Hydroxychloroquine to Treat Nonalcoholic Steatohepatitis), which is not on this map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Using Hydroxychloroquine to Treat Nonalcoholic Steatohepatitis
Who cites it
26 citing papers in PubMed, 47 citations in OpenAlex.
- 14-Deoxy-11,12-didehydroandrographolide Attenuates Lipotoxicity and Non-Alcoholic Steatohepatitis Through Restoration of Autophagy and Reduction in Oxidative Stress.International journal of molecular sciences · 2026Article
- Inhibition of lysosomal LAMTOR1 increases autophagy by suppressing the MTORC1 pathway to ameliorate lipid accumulations in MAFLD.Autophagy · 2025Article
- Novel prolyl endopeptidase inhibitor fromRSC advances · 2025Article
- Vincamine induces cytoprotective autophagy via regulation of ampk/mtor signaling pathway in gentamicin-induced hepatotoxicity and nephrotoxicity in rats.Scientific reports · 2025Article
- Review
- Mechanisms underpinning the effect of exercise on the non-alcoholic fatty liver disease: review.EXCLI journal · 2025Review
- Article
- Systems metabolic insights into kaempferol-mediated alleviation of alcoholic fatty liver disease.Frontiers in endocrinology · 2025Article
- Natural active botanical metabolites: targeting AMPK signaling pathway to treat metabolic dysfunction-associated fatty liver disease.Frontiers in pharmacology · 2025Review
- β-caryophyllene sensitizes hepatocellular carcinoma cells to chemotherapeutics and inhibits cell malignancy through targeting MAPK signaling pathway.Frontiers in pharmacology · 2024Article
- Investigation of Non-Coding RNA-Related Autophagy Alterations in Drug-Resistant Multiple Myeloma Plasma Cells.Iranian journal of pathology · 2024Article
- Autophagy and hepatic lipid metabolism: mechanistic insight and therapeutic potential for MASLD.npj metabolic health and disease · 2024Review
- The pivotal role of dysregulated autophagy in the progression of non-alcoholic fatty liver disease.Frontiers in endocrinology · 2024Review
- Involvement of Lipophagy and Chaperone-Mediated Autophagy in the Pathogenesis of Non-Alcoholic Fatty Liver Disease by Regulation of Lipid Droplets.International journal of molecular sciences · 2023Review
- Article
- Emerging mechanistic insights of selective autophagy in hepatic diseases.Frontiers in pharmacology · 2023Review
- Per- and polyfluoroalkyl substances activate UPR pathway, induce steatosis and fibrosis in liver cells.Environmental toxicology · 2023Article
- Digging out the biology properties of tRNA-derived small RNA from black hole.Frontiers in genetics · 2023Review
- Methylsulfonylmethane ameliorates metabolic-associated fatty liver disease by restoring autophagy flux via AMPK/mTOR/ULK1 signaling pathway.Frontiers in pharmacology · 2023Article
- Paraoxonase-2 contributes to promoting lipid metabolism and mitochondrial function via autophagy activation.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Autophagy is a conserved catabolic process that eliminates dysfunctional cytosolic biomolecules through vacuole-mediated sequestration and lysosomal degradation. Although the molecular mechanisms that regulate autophagy are not fully understood, recent work indicates that dysfunctional/impaired autophagic functions are associated with the development and progression of nonalcoholic fatty liver disease (NAFLD), alcoholic fatty liver disease (AFLD), and hepatocellular carcinoma (HCC). Autophagy prevents NAFLD and AFLD progression through enhanced lipid catabolism and decreasing hepatic steatosis, which is characterized by the accumulation of triglycerides and increased inflammation. However, as both diseases progress, autophagy can become impaired leading to exacerbation of both pathological conditions and progression into HCC. Due to the significance of impaired autophagy in these diseases, there is increased interest in studying pathways and targets involved in maintaining efficient autophagic functions as potential therapeutic targets. In this review, we summarize how impaired autophagy affects liver function and contributes to NAFLD, AFLD, and HCC progression. We will also explore how recent discoveries could provide novel therapeutic opportunities to effectively treat these diseases.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.